ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

SLN Silence Therapeutics Plc

535.00
0.00 (0.00%)
Last Updated: 00:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Silence Therapeutics Plc LSE:SLN London Ordinary Share GB00B9GTXM62 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 535.00 521.00 524.00 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Silence Therapeutics PLC New divisional patent and injunction application (4886D)

10/10/2018 7:00am

UK Regulatory


Silence Therapeutics (LSE:SLN)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Silence Therapeutics Charts.

TIDMSLN

RNS Number : 4886D

Silence Therapeutics PLC

10 October 2018

Silence Therapeutics Announces Receipt of a New European Notice of Intention to Grant a Patent and the Launch of an Interim European Injunction Application against Onpattro(TM)

October 10 2018

LONDON, Silence Therapeutics plc, (LON:SLN) ("Silence" or "the Company") a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, confirms the receipt of a notice of intention to grant for a new European divisional patent, EP 3 222 724B, and further said that it has commenced a new cross-border interim injunction application in the Netherlands against Alnylam's Onpattro(TM) (patisiran).

Silence received a notice of intention to grant from the European Patent Office for patent application EP 3 222 724B, further strengthening its innovative chemical modification technology patent family in Europe, which sits at the heart of the current therapeutic siRNA field.

Silence has further filed a cross-border interim injunction application in the Netherlands (where Alnylam holds its Marketing Authorisation for Onpattro(TM)), requesting the courts to prohibit Alnylam from commercialising Onpattro(TM) across Europe until the resolution of the trial to determine infringement of EP 3 222 724B by Onpattro(TM). Despite requests not to do so, Alnylam has openly commercialised Onpattro(TM) in the face of the Silence claims. The Company therefore feels that it has been left with no alternative other than to take the necessary steps to enforce its patents and protect the historic investment made in its technology.

Onpattro(TM) remains accused of infringement of Silence European Patent EP 1 847 547B in the United Kingdom and Portugal and Silence is seeking injunctive relief in these territories to restrain Alnylam's infringement. The UK trial is to be held in December 2018, with a decision expected in early 2019. While Silence continues to protect its rights and inventions, the Company remains focused on executing its core business of drug discovery and development to continue to build its therapeutic pipeline.

David Horn Solomon, Chief Executive Officer of Silence Therapeutics, commented:

"Silence continues to innovate with new, competitive RNAi medicines. During 2017 & 2018, the European Patent Office has upheld the validity of our expanding patent estate with the granting of additional patents around our foundational chemical modification IP.

When companies openly promote new product commercialisation in the face of relevant granted patent rights, Silence Therapeutics will take steps to enforce its patents and protect the historic investment made in its technology."

Enquiries:

 
 Silence Therapeutics plc                       Tel: +44 (0)20 3457 
  Dr David Horn Solomon, Chief Executive         6900 
  Officer 
  David Ellam, Chief Financial Officer 
 
 Peel Hunt LLP (Nominated Adviser and Broker)   Tel: +44 (0)20 7418 
  James Steel/Oliver Jackson                     8900 
 European IR                                    Tel: +44 (0) 20 
  Consilium Strategic Communications             3709 5700 
  Mary-Jane Elliott / Angela Gray 
  silencetherapeutics@consilium-comms.com 
 US IR                                           Tel: +1 (212) 213-0006 
  Burns McClellan 
  Lisa Burns, Jill Steier, John Grimaldi 
  Silence.therapeutics@burnsmc.com 
 

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural

mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively

inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using

its enabling delivery systems, it has achieved an additional level of specificity by delivering its

therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and

delivery systems are designed to improve the stability of our molecules and enhance effective delivery

to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

For more information, please visit: https://www.silence-therapeutics.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCUGGWCUUPRPUB

(END) Dow Jones Newswires

October 10, 2018 02:00 ET (06:00 GMT)

1 Year Silence Therapeutics Chart

1 Year Silence Therapeutics Chart

1 Month Silence Therapeutics Chart

1 Month Silence Therapeutics Chart

Your Recent History

Delayed Upgrade Clock